← Back to patent-cliff list
Hydroxychloroquine sulfate/Sirolimus
Tier C — Watch / tradeHydroxychloroquine sulfate/Sirolimus
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：mTORC1, mTORC2
Brand：Siroquine
Indications (approved)：Glioblastoma
Regional status
US
Phase III
2021-08-23
EU
-
China
Phase I
2024-05-10
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Hydroxychloroquine sulfate/Sirolimus?
Approved indications include: Glioblastoma.
When does the Hydroxychloroquine sulfate/Sirolimus patent expire?
No public expiry year is available for Hydroxychloroquine sulfate/Sirolimus yet; this page updates once verified.
How do I get a quote for Hydroxychloroquine sulfate/Sirolimus intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21